Exhibit 99.1

CIPHERGEN  LOGO

                                                           FOR IMMEDIATE RELEASE


            CIPHERGEN BIOSYSTEMS ANNOUNCES RESULTS OF ANNUAL MEETING

Fremont, Calif., July 6, 2007 - Ciphergen Biosystems, Inc. (Nasdaq: CIPH)
announced today that at its annual meeting held on June 29, 2007, its
stockholders elected Michael J. Callaghan, Kenneth J. Conway, and James L.
Rathmann as Class I directors for three-year terms and ratified the appointment
of PricewaterhouseCoopers LLP as the Company's independent registered public
accounting firm for the year ending December 31, 2007. Ciphergen stockholders
also approved amendments to the company's certificate of incorporation to
increase the authorized shares of capital stock to 155,000,000 and the
authorized number of shares of common stock to 150,000,000, and to change the
name of the company to Vermillion, Inc. In connection with the name change,
which is expected to become effective mid-August 2007, the company has reserved
the Nasdaq ticker symbol VRML.

"We believe the name change reflects the significant transformation that has
occurred over the last year, and provides a new foundation from which to build a
high-value diagnostics company," said Gail S. Page, Chief Executive Officer and
President. "Vermillion signifies health, life, passion and our commitment to
improving patient health."

About Ciphergen

Ciphergen Biosystems, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Ciphergen, along with its
scientific collaborators, has ongoing diagnostic programs in
oncology/hematology, cardiology and women's health with an initial focus in
ovarian cancer. Ciphergen is based in Fremont, California. More information
about Ciphergen can be found on the Web at: http://www.ciphergen.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve significant
risks and uncertainties, including those that can be found in Ciphergen's Form
10-K for the year ended December 31, 2006, and in Ciphergen's periodic reports
on Form 10-Q and Form 8-K. Statements in this release are based upon information
available to Ciphergen as of the date of the release.

Information and announcements involving Ciphergen's expectations, beliefs,
hopes, plans, intentions or strategies regarding the future are forward-looking
statements for purposes of the safe harbor provisions under the Private
Securities Litigation Reform Act of 1995. We claim the protection of such safe
harbor, and disclaim any intent or obligation to update any forward-looking
statement contained in this document as a result of new information, future
events or otherwise. These statements are not guarantees of future performance
and actual results could differ materially from our current expectations.

NOTE: Ciphergen is a registered trademark of Ciphergen Biosystems, Inc.